Philips, C. | bioRxiv Science

bioRxiv2025

EcoKMER: One-stop shop for spatio-temporal metagenomic exploration using DataFed

Spatially distributed environmental sampling generates highly complex and multidimensional datasets illuminating key insights into microbial diversity, evolutionary-coevolutionary processes, and host-pathogen interactions. While these sampling methods generate high value datasets, dataset size, the dataset integration, visualization, analysis, and provenance tracking present significant bottlenecks to scientific discovery. To address this bottleneck, we developed EcoKMER, an R-Shiny front-end application designed to streamline metagenomic data accessibility and provide geospatial context to data in support of hypothesis-driven investigations into environmental sampling, supported by DataFed as its back-end data management platform. EcoKMER enables interactive visualization and filtering of harmonized metagenomic data and metadata using an interoperable approach, allowing users to extract spatially distributed sample-based metadata on top of environmental parameters such as geolocation, temperature, pH, for investigating ecological changes across time and space enhancing sample processing methods. As an example, we deployed this tool to track analysis of metagenomes from the organisms in the Salish Sea Estuary, consistent with existing community-accepted standards. Built on top of DataFed, a flexible and robust scientific data management system built for data lakehouse architectures, EcoKMER is positioned as a powerful tool to improve sampling strategy decision making, accelerate new insights for collaborative biological and environmental research, and fostering AI-ready analyses designed to enhance discovery and guidance for bioeconomic engineering. The published manuscript is available at https://www.osti.gov/biblio/3412938

bioinformatics↗

bioRxiv2025

CD47 blockade enhances immunoradiotherapy response in head and neck squamous cell carcinoma

Head and neck squamous cell carcinoma (HNSCC) is a significant cause of morbidity and mortality worldwide, with limited treatment options for patients with locally advanced disease. CD47 immune checkpoint inhibitors have been used to block the CD47/SIRPa interaction that inhibits antigen-presenting cell phagocytosis, thereby enhancing antigen presentation to cytotoxic T-cells, and have shown promise in combination with anti-PD1 immunotherapy in tumors, including recurrent/metastatic HNSCC. We found that CD47 expression is associated with poor prognosis in HNSCC and explored the anti-tumor activity of CD47 blockade in combination with anti-PD1 and lymphatic-sparing radiotherapy in a locally advanced HNSCC model. Using the 4MOSC1 orthotopic, syngeneic murine model of HPV-negative HNSCC, treatment with an engineered CD47-blocking SIRP fusion protein (ALX301) similarly induced complete tumor regression in combination with anti-PD1, and a partial response as a standalone therapeutic. An anti-PD1 immune checkpoint inhibitor in a CD47-null tumor background led to complete tumor regression confirming a key role for CD47 in tumor immunity. Anti-CD47 treated mice demonstrated increased MHC-II expression on dendritic cells within the tumor and upregulation of CD86 co-stimulatory molecule on dendritic cells within the tumor, sentinel lymph nodes, and contralateral lymph nodes. Combination ALX301 and anti-PD1 treatment in an anti-PD1 resistant 4MOSC2 model demonstrated significant tumor regression, enhanced survivability, improved response with neoadjuvant radiotherapy, and greater retention of CD8+ T-cells within the tumor microenvironment. Notably, T-cell receptor sequencing revealed increased shared clonality between the tumor and sentinel lymph nodes of anti-CD47 treated mice. These data demonstrate that a combination of CD47 blockade and anti-PD1 therapy enhances tumor antigen presentation and immune cell infiltration, while further improving anti-tumor responses in combination with tumor-targeted radiotherapy. This study provides support for the rational design of combinatorial immunoradiotherapy, using anti-CD47 inhibitors and anti-PD1 therapy, in a clinical trial targeting locally advanced HPV-negative HNSCC.

cancer biology↗